Last reviewed 03/2021

  • dexfenfluramine was previously used as an adjunct to dietary treatment for severe obesity. It is the dextrorotatory stereo isomer of fenfluramine, inhibiting the re-uptake and stimulates the release of 5-HT in the hypothalamus which is involved in appetite and feeding behaviour
  • primary pulmonary hypertension and heart valve disorders are recognised to be associated with the use of anorectic agents
  • dexfenfluramine and fenfluramine were withdrawn in October 1997 because of the evidence associated with development of valvular disorders and pulmonary hypertension